New aromatase inhibitors for the treatment of breast cancer;Wirkungsweise und stellenwert der neuen aromatasehemmer in der therapie des mammakarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 59, Issue 6, 1999, Pages 245-254

  Friedrichs, Kay ^a   Holzel F ^b   Janicke F ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; CORTICOTROPIN; CYTOCHROME P450; ESTRADIOL; ESTROGEN; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

AROMATIZATION; BREAST CANCER; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; HORMONE INHIBITION; HORMONE SENSITIVITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; REVIEW;

EID: 0344299153     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-14198     Document Type: Review

References (97)

1. Beatson, G. T.: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2 (1896) 104-107.
2. Bounter, F., E. Ricart, A. Linch: Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J. Clin. Oncol. 10 (1992) 438-446.
3. Bradlow, H. L.: A reassessment of the role of breast tumor aromatization. Cancer Res. 42 (1982) 3382-3386.
4. Brodie, A. M. H., C. Lancope: Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3, 17-dione. Endocrinology 106 (1980) 19-21.
5. Brodie, A. M. H., W. M. Garrett, J. R. Hendrickson, et al.: Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3, 17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo. Steroids 38 (1981) 693-702.
6. Brueggemeier, R. W.: Biochemical and molecular aspects of aromatase. J. Enzym. Inhib. 4 (1990) 101-111.
7. Buzdar, A., W. Jonat, A. Howell, et al.: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials. J. Clin. Oncol. 7 (1996) 2000-2011.
8. Buzdar, A. U., S. E. Jones, C. L. Vogel, J. Wolter, P. Plourde, A. Webster for the Arimidex Study Group: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advancd breast carcinoma. Cancer 79 (1997) 730-739.
9. Buzdar, A. U., G. Hortobagyi: Update on endocrine therapy for breast cancer. Clin. Cancer Res. 4 (1998) 527-534.
10. Buzdar, A. U.: Anastrozole: A new addition to the armamentarium against advanced breast cancer. Amer. J. Clin. Oncol. 21 (1998) 161-166.
11. Buzdar, A. U., W. Jonat, A. Howell, S.E. Jones, C. P. Blomqvist, C. L. Vogel, W. Eiermann, J. M. Wolter, M. Steinberg, A. Webster, D. Lee for the Arimidex Study Group: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 83 (1998) 1142-1152.
12. Cash, R., A. J. Brough, M. N. P. Cohen, P. S. Satoh: Aminoglutethimide (Elipten-CIBA) as an inhibitor of adrenal steroidogenesis. Mechanism of action and therapeutic trial. J. Clin. Endocrinol. Metab. 27 (1967) 1239-1268.
13. Chalbos, D., F. Vignon, I. Keydar, H. Rochefort: Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J. Clin. Endocrinol. Metab. 55 (1982) 276-283.
14. Daffada, A. A. I., S. R. D. Johnston, I. E. Smith, S. Detre, N. King, M. Dowsett: Exon-5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 55 (1995) 288-293.
15. Demers, L. M., J. C. Melby, T. E. Wilson, et al.: The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J. Clin. Endocrinol. Metab. 70 (1990) 1162-1166.
16. DeSombre, E. R., S. M. Thorpe, C. Rose, R. R. Blough, K. W. Andersen, B. B. Rasmussen, W. J. King: Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res. 46 (1986) 4256-4264.
17. Dixon, J. M., C. D. B. Love, S. Tucker, D. Bellamy, D. Cameron, W. R. Miller, R. C. F. Leonard: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res. Treatm. 46 (1997) 213.
18. Dombernowsky, P., I. Smith, G. Falkson, R. Leonard, L Panasci, J. Bellmunt, W. Bezwoda, G. Gardin, A. Gudgeon, H.A. Chaudri, U. Hornberger for the Letrozole International Trial Group: Double-blind trial in postmenopausal (pmp) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA). Proc. 32nd Ann. Meeting Amer. Soc. Clin. Oncol. 15 (1996) 100.
19. Dombernowsky, P., I. Smith, G. Falkson, R. Leonard, L. Panasci, J. Bellmunt, W. Bezwoda, G. Gardin, A. Gudgeon, M. Morgan, A. Fornasiero, W. Hoffmann, J. Michel, T. Hatschek, T. Tjabbes, H. A. Chaudri, U. Hornberger, P. F. Trunet: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16 (1998) 453-461.
20. Dowsett, M., R. C. Stein, R. C. Coombes,: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid. Biochem. Mol. Biol. 43 (1992) 155-159.
21. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 1-15 and 71-85.
22. Ehrlichman, C., C. L. Loprinzi: Hormonal therapies. In: De Vita, jr., V. T., S. Hellman, S. A. Rosenberg (eds.) Cancer, Principles and Practice of Oncology, 5th Ed. Philadelphia, New York Lippincott-Raven (1997) 395-405.
23. Engel, L. W., N. A. Young, T. S. Tralka, M. E. Lippman, S. J. O'Brien, M. J. Joyce: Establishment and characterization of three new continuous cell lines derived from human carcinomas. Cancer Res. 38 (1978) 3352-3364.
24. Fisher, B., J. P. Constantino, C. K. Redmond: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Survey Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537.
25. Fishman, J., E. F. Hahn: The nature of the final oxidative step in the aromatization sequence. Steroids 50 (1987) 339-345.
26. Folkman, J.: Tumor angiogenesis. In: Mendelson, J., P. M. Howley, M. A. Israel, L A. Liotta (eds.) The Molecular Basis of Cancer. Philadelphia W. B. Saunders (1995) 206-232.
27. Fuqua, S. A. W., S. D. Fitzgerald, G. C. Chamness, et al.: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51 (1991) 105-109.
28. Fuqua, S. A. W., C. Wiltschke, C. Castles, D. Wolf, D. C. Allred: A role for estrogen-receptor variants in endocrine resistance. Endocrine-Related Cancer 2 (1995) 19-25.
29. Gershanovich, M., H.A. Chaudri, U. Homberger, M. Lassus for the AR/BC2 and AR/BC3 International Study Groups: Comparison of letrozole 2.5 mg (Femara®) with megestrol acetate (MA) and with aminoglutethimide (AG) in patients with visceral disease. Breast Cancer Res. Treat. 46 (1997) 212.
30. Gershanovich, M., H. A. Chaudri, D. Campos, H. Lurie, A. Bonaventura, M. Jeffrey, F. Buzzi, I. Bodrogi, H. Ludwig, P. Reichardt, N. O'Higgins, G. Romieu, P. Friedrich, M. Lassus for the International Trial Group (AR/BC3): Letrozole, a new oral aromatase inhibitor: Randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol. 9 (1998) 639-645.
31. Goldhirsch, A., R. D. Gelber: Endocrine therapies of breast cancer. Sem. Oncol. 23 (1996) 494-505.
32. Goss, P. E., M. Jarman, J. R. Wilkinson, et al.: Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J. Steroid. Biochem. 24 (1986) 619-622.
33. Goss, P. E., K. M. E. H. Gwyn: Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol. 12 (1994) 2460-2470.
34. Graham, M. L., J. A. Smith, P. B. Jewett, et al.: Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: Analysis by quantitative dual parameter flow cytometry. Cancer Res. 52 (1992) 593-601.
35. Griffiths, C. T., T. C. Hall, Z. Saba, et al.: Preliminary trial of aminoglutethimide in breast cancer. Cancer 32 (1973) 31-37.
36. Hackenberg, R., S. Lüttchens, J. Hofmann, R. Kunzmann, F. Hölzel, K.-D. Schulz: Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res. 51 (1991) 5722-5727.
37. Harris, A. L., M. Dowsett, S. L. Jeffcoate, et al.: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab. 55 (1982) 718-722.
38. Harris, A. L.: Aminoglutethimide - a new endocrine therapy in breast cancer. Exp. Cell Biol. 53 (1985) 1-8.
39. Harvey, H. A., R. J. Santen, J. Osterman: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43 (1979) 2207-2214.
40. Henderson, I. C.: Endocrine treatment of metastatic breast cancer. In: Harris, J. R., S. Hellman, I. C Henderson, D. W. Kinne (eds.) Breast Diseases. 2nd ed. Philadelphia J. B. Lippincott (1991) 559-603.
41. Höffken, K., W. Jonat, K. Possinger, M. Kölbel, T. Kunz, H. Wagner, R. Becher, R. Callies, P. Friedrich, W. Willmanns: Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: A phase II study. J. Clin. Oncol. 8 (1990) 875-880.
42. Horwitz, K. B., M. E. Costlow, W. L. McGuire,: MCF-7: A human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptors. Steroids 26 (1975) 785-795.
43. Howell, A., A. Buzdar, W. Jonat, A. Webster, M. von Euler for the Arimidex International Study Group: Significantly improved survival with "Arimidex" (anastrozole [AN]) compared with megestrol acetate in postmenopausal women with advanced breast cancer (ABC): Updated results of two randomized trials. Breast Cancer Res. Treat. 46 (1997) 27.
44. Jensen, E. V., E. R. DeSombre, P. W. Jungbluth: Estrogen receptors in hormone-responsive tissues and tumors. In: Wissler, R., T. L. Dao, S. Wood (eds.) Endogenous Factors Influencing Host-Tumor Balance. Chicago Univ. Chicago Press (1967) 15-30.
45. Jensen, E. V., S. Smith, E. R. DeSombre: Hormone dependency in breast cancer. J. Steroid. Biochem. 7 (1976) 911-917.
46. Jensen, E. V., E. R. DeSombre: Steroid hormone binding and hormone receptors. In: Holland, J. F., E. Frei III, R. C. Bast Jr., D. W. Kufe, D. L. Morton, R. R. Weichselbaum (eds.) Cancer Medicine, 4th ed. Baltimore Williams & Wilkins (1997) 1049-1059.
47. Jonat, W., A. Howell, C. Blomqvist, W. Eiermann, G. Winblad, C Tyrell, L. Mauriac, H. Roche, S. Lundgren, R. Hellmund, M. Azab on behalf of the ARIMIDEX study group: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Europ. J. Cancer 32 A (1996) 404-412.
48. Jordan, V. C., W. H. Catherino, D. M. Wolf: Drug resistance to tamoxifen: Mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth. Endocrine-Related Cancer 2 (1995) 45-51.
49. Kaufmann, M., W. Jonat, U. Kleeberg, H. Eidtmann, F. Jaenicke, J. Hilfrich, R. Kreienberg, M. Albrecht, H. K. Weitzel, H. Schmid, P. Strunz, E. Schachner-Wuenschmann, G. Bastert, H. Maass: The German Zoladex trial group: Goserelin, a depot gonadotropin releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 7 (1989) 1113-1119.
50. Keydar, I., L Chen, S. Karby, F. R. Weiss, J. Delarea, M. Radu, S. Chaitcik, H. J. Brenner: Establishment and characterization of a cell line of human breast carcinoma origin. Europ. J. Cancer 15 (1979) 659-670.
51. Knight, W. A., R. B. Livingston, E. J. Gregory, W. L. McGuire: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37 (1977) 4669-4671.
52. Kuiper, G. G. J. M., E. Enmark, M. Pelto-Huikko, S. Nilsson, J. Å. Gustafsson: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93 (1996) 5925-5930.
53. Kuiper, G. G. J. M., B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, S. Nilsson, J. Å. Gustafsson: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 (1997) 863-870.
54. Levenson, A. S., V. C. Jordan: MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res. 57 (1997) 3071-3078.
55. Lippman, M. E., G. Bolan, K. Huff: The effect of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36 (1976) 4595-4601.
56. Lipton, A., R. J. Santen: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33 (1974) 503-512.
57. Maass, H., B. Engel, H. Hohmeister, F. Lehmann, G. Trams: Estrogen receptors in human breast cancer tissue. Amer. J. Obstet. Gynecol. 113 (1972) 377-382.
58. Maass, H., W. Jonat, G. Stolzenbach, G. Trams: The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 46 (1980) 2835-2837.
59. Mahfoudi, A., E. Roulet, S. Dauvois, M.G. Parker, W. Wahli: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. USA 92 (1995) 4206-4210.
60. McGuire, W. L., P. P. Carbone, M. E. Sears, G. C. Escher: Estrogen receptors in human breast cancer: An overview. In: McGuire, W. L., P. P. Carbone, E. P. Vollmer (eds.) Estrogen Receptors in Human Breast Cancer. New York Raven Press (1975) 1-7.
61. Miller, W. R., R. A. Hawkins, A. P. M. Forrest: Significance of aromatase activity in human breast cancer. Cancer Res. 42 (Suppl.) (1982) 3365-3368.
62. Miller, W. R.: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev. 16 (1989) 83-93.
63. Miller, W. R., E. C. Anderson: The biological relevance of aromatase activity in breast tumours. In: Robustelli, G., A. Manni, F. Pannuti (eds.) Clinical Use of Aromatase Inhibitors. Pavia Edimes (1994) 89-93.
64. Miller, W. R., J. Telford, C. Love, R. C. F. Leonard, S. Hillier, M. A. Bischoff, H. Gundacker, J. M. Dixon: The effects of letrozole on in situ and in vitro oestrogen synthesis and endogenous oestrogen within the breast. Breast Cancer Res. Treat. 46 (1997) 54.
65. Montgomery, P. A., G. K. Scott, M. C. Luce, M. Kaufmann, C. C. Benz: Human breast tumors containing non-DNA binding immunoreactive (67 kDa) estrogen receptor. Breast Cancer Res. Treat. 26 (1993) 181-189.
66. Mouridsen, H., T. Palshof, J. Patterson, et al.: Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 5 (1978) 131-141.
67. Muss, H. B.: Endocrine therapy of advanced breast cancer: A review. Breast Cancer Res. Treat. 21 (1992) 15-22.
68. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years. Lancet 1 (1983) 257-261.
69. O'Neill, J. S., J. Johnson, B.W. Metcalf: Aromatase: A target enzyme in breast cancer. In: Sunkara, P. S. (ed.) Novel Approaches to Cancer Chemotherapy. New York Academic Press (1984) 307-328.
70. O'Neill, J. S., W. R. Miller: Aromatase activity in breast adipose tissue from women with benign and malignant disease. Brit. J. Cancer 56 (1987) 601-604.
71. O'Reilly, M. S., L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage, J. Folkman: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328.
72. Perez Carrion, R., V. Alberola Candel, F. Calabresi, et al.: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann. Oncol. 5 (Suppl.) (1994) 519-524.
73. Possinger, K., M. Gershanovich, D. Carnpos, et al.: Letrozole (Femara) a new potent, selective aromatase inhibitor (AI): Superior to another Al, aminoglutethimide (AC), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy. Europ. J. Cancer 33 (Suppl. 8) (1997) 643.
74. Rausch, D. J., D. T. Kiang, B. J. Kennedy: Guidelines for the management of breast cancer: A treatment summary. In: Kennedy, B. J. (ed.) Breast Cancer. New York H. Liss (1989) 225-239.
75. Rosenberg, S. A., P. Spiess, R. Lafreniere: A new approach to the adaptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223 (1986) 1318-1321.
76. Rosenberg, S. A.: Principles of cancer management: Biologic therapy. In: DeVita, Jr., V. T., S. Hellman, S. A. Rosenberg (eds.) Cancer, Principles and Practice of Oncology, 5th ed. Philadelphia, New York Lippincott-Raven (1997) 349-373.
77. Santen, R. J., A. Lipton, J. Kendall: Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. J. Amer. Med. Assn. 230 (1974) 1661-1665.
78. Santen, R. J., S. Santner, B. Davis, J. Veldhuis, E. Samojlik, E. Ruby: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. J. Clin. Endocrinol. Metab. 47 (1978) 1257-1265.
79. Santen, R. J., E. Samojlik, S. A. Wells: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab. 51 (1980) 473-477.
80. Santen, R. J., A. Manni, H. Harvey: Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res. Treat. 7 (1986) 129-145.
81. Santen, R. J.: Clinical use of aromatase inhibitors: Current data and therapeutic perspectives. J. Enzym. Inhib. 4 (1990) 79-99.
82. Santen, R. J.: Clinical use of aromatase inhibitors in human breast carcinoma. J. Steroid. Biochem. Mol. Biol. 40 (1991) 247-253.
83. Santen, R.J., J. Martel, M. Hoagland, F. Naftolin, L. Roa, N. Harad, L. Hafer, R. Zaino, S. J. Santner: Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79 (1994) 627-632.
84. Schintzinger, U.: Carcinoma mammae. Cbl. Chir. 16 (1889) 55.
85. Schmidt-Matthiesen, H., G. Bastert (Hrsg.): Gynäkologische Onkologie. 4. Aufl. Stuttgart Schattauer (1993) 99.
86. Simon, W. E., M. Albrecht, F. Hölzel: Development of resistance to tamoxifen and progestins in human mammary cancer. Proc. 13th Int. Cong. Chemother. Vienna 270 (1983) 1-4.
87. Simon, W. E., M. Albrecht, G. Trams, M. Dietel, F. Hölzel: In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J. Natl. Cancer Inst. 73 (1984) 313-321.
88. Simon, W. E., M. Hänsel, M. Dietel, L. Matthiesen, M. Albrecht, F. Hölzel: Alteration of steroid hormone sensitivity during the cultivation of human mammary carcinoma cells. In Vitro 20 (1984) 157-166.
89. Simon, W. E., M. Albrecht, F. Hölzel: Langzeit-Zellkultur als Modell der Resistenzentwickung gegen endokrine Faktoren beim Mammakarzinom. In: Jonat, W., M. Kaufmann, F. Kubli, H. Maass (Hrsg.) Aktuelle Onkologie 16. München Zuckschwerdt (1985) 230-239.
90. Sluyser, M., J. L. Wittliff: Influence of estrogen receptor variants in mammary carcinomas on the prognostic reliability of the receptor assay. Mol. Cell. Endocrinol. 85 (1992) 83-88.
91. Smith, I., P. Dombernowsky, G. Falkson, R. Leonard, et al.: Double-blind trial in postmenopausal (pmp) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2,5 mg letrozole over megestrol acetate (MA). Europ. J. Cancer 32A (Suppl.2) (1996) 8-13
92. Soule, H. D., J. Vasquez, A. Long, S. Albert, M. J. Brennan: A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51 (1973) 1409-1413.
93. Stein, R. C., M. Dowsett, A. Hedley, et al.: The clinical and endocrine effects of 4-hydroxy-androstenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Brit. J. Cancer 62 (1990) 679-683.
94. Thompson, E. A., P. K. Siiteri: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249 (1974) 5364-5372.
95. Vermeulen, A., V. A. Giagulli, P. De Schepper, A. Buntinx, E. Stoner: Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. The Prostate 14 (1989) 45-53.
96. Wells, S. A., R. J. Santen, A. Lipton, et al.: Medical adrenalectomy with aminoglutethimide: Clinical trials in postmenopausal patients with metastatic breast cancer. Ann. Surg. 187 (1978) 475-484.
97. Yates, R. A., M. Dowsett, G. V. Fisher, A. Selen, P. J. Wyld: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Brit. J. Cancer 73 (1996) 543-548.